Literature DB >> 2732000

Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers.

T Kondo1, H Kono, N Miyamoto, R Yoshida, H Toki, I Matsumoto, M Hara, H Inoue, A Inatsuki, T Funatsu.   

Abstract

We have surveyed the incidence of adult T-cell leukemia/lymphoma (ATLL) in an endemic area of 290,464 inhabitants for 7 years. We now revise our previous results on the basis of additional findings and estimate the age- and sex-specific cumulative rate for HTLV-I carriers, the adoption of which is recommended by current cancer epidemiology as a new age-standardized incidence rate. An unequivocal age-dependent increase in seroprevalence was observed for both sexes with a characteristic predominance in females. The age-dependent seroconversion in females may be partly explained by additional infection from infected husbands to their wives but the reason for men remains obscure. The mean annual number of incident cases of ATLL was 11.4, giving 3.9 ATLL patients annually per 10(5) inhabitants, 6.1 per 10(5) inhabitants aged over 30, and 85.0 per 10(5) seropositives aged over 30. Crude annual incidence rate of ATLL among 10(5) male seropositives aged over 30 was 145.3 and that for females was 55.2 and 95% confidence intervals of ATLL incidence rates were 34.8 to 255.7 for males and 6.4 to 104.1 for females, respectively. Although the sex ratio of 80 ATLL patients was 1.35, males are more prone to the disease (46 male patients among 4,522 male seropositives aged over 30 vs 34 female patients among 8,801 female seropositives aged over 30; p less than 0.001) for unknown reason(s). Morbidity in male seropositives aged over 30 is 2.6 times as high as that of females. Decennial incidence rates in males in their fifties and sixties were significantly higher than those in females. The remarkable male preponderance in oncogenicity of HTLV-I may be due to the fact that men are more prone to the disease and the number of female carriers in the denominator used to calculate the incidence rate is larger than that of males. The whole life span (0-79) cumulative risk for males was 6.9% and significantly higher than that of females (2.95%).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732000     DOI: 10.1002/ijc.2910430618

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

Review 1.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

2.  HTLV-I infection in French West Indies: a case-control study.

Authors:  N Frery; M Chavance; I Valette; L Schaffar; C Neisson-Vernant; J Jouannelle; N Monplaisir
Journal:  Eur J Epidemiol       Date:  1991-03       Impact factor: 8.082

Review 3.  Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation.

Authors:  Michael D Lairmore; Lee Silverman; Lee Ratner
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

4.  Follow-up of asymptomatic HTLV-I carriers among blood donors in Kyushu, Japan.

Authors:  S Tokudome; Y Maeda; K Fukada; D Teshima; T Asakura; E Sueoka; Y Motomura; Y Kusumoto; Y Imamura; T Kiyokawa
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

Review 5.  Genome editing and the next generation of antiviral therapy.

Authors:  Daniel Stone; Nixon Niyonzima; Keith R Jerome
Journal:  Hum Genet       Date:  2016-06-08       Impact factor: 4.132

6.  Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis.

Authors:  J K Cruickshank; J H Richardson; O S Morgan; J Porter; P Klenerman; J Knight; A L Newell; P Rudge; A G Dalgleish
Journal:  BMJ       Date:  1990-02-03

Review 7.  "Antivirals" in the treatment of adult T cell leukaemia- lymphoma (ATLL).

Authors:  Paul A Fields; Graham P Taylor
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

8.  Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection.

Authors:  Mayumi Tokunaga; Hirofumi Uto; Kohei Oda; Masahito Tokunaga; Seiichi Mawatari; Kotaro Kumagai; Kouichi Haraguchi; Makoto Oketani; Akio Ido; Nobuhito Ohnou; Atae Utsunomiya; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2014-01-25       Impact factor: 7.527

Review 9.  Cancer burden and trends in the Asian Pacific Rim region.

Authors:  Binh H Yang; D Maxwell Parkin; Lin Cai; Zuo Feng Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2004 Apr-Jun

Review 10.  Human T lymphotropic virus type 1 uveitis.

Authors:  M Mochizuki; K Tajima; T Watanabe; K Yamaguchi
Journal:  Br J Ophthalmol       Date:  1994-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.